ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "B-Lymphocyte"

  • Abstract Number: L16 • ACR Convergence 2024

    Dapirolizumab Pegol Demonstrated Significant Improvement in Systemic Lupus Erythematosus Disease Activity: Efficacy and Safety Results of a Phase 3 Trial

    Megan Clowse1, David Isenberg2, Joan Merrill3, Thomas Dörner4, Michelle Petri5, Edward Vital6, Eric Morand7, Teri Jimenez8, Stephen Brookes9, Janine Gaiha-Rohrbach10, Christophe Martin11, Annette Nelde12 and Christian Stach13, 1Division of Rheumatology and Immunology, Duke University, Durham, NC, 2Department of Ageing, Rheumatology and Regenerative Medicine, Division of Medicine, University College London, London, United Kingdom, 3Oklahoma Medical Research Foundation, Oklahoma City, OK, 4Department of Medicine/Rheumatology and Clinical Immunology, Charité Universitätsmedizin Berlin, Berlin, Germany, 5Johns Hopkins University School of Medicine, Baltimore, MD, 6Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, 7Centre for Inflammatory Diseases, Monash University, Melbourne, Australia, 8UCB, Raleigh, NC, 9Biogen, Maidenhead, United Kingdom, 10Biogen, Cambridge, MA, 11UCB, Slough, United Kingdom, 12Biogen, Baar, Switzerland, 13UCB, Monheim am Rhein, Germany

    Background/Purpose: Dapirolizumab pegol (DZP) is a novel, polyethylene glycol (PEG)-conjugated antigen-binding (Fab') fragment, lacking an Fc domain, that inhibits CD40L signaling. By binding to CD40L,…
  • Abstract Number: 0012 • ACR Convergence 2024

    Dichotomous Expression of CXCR3 and CCR9 and Relationship to Intestinal Permeability in B Cells in Rheumatoid Arthritis

    Ken Yasaka, Ruoqiao Wang, Nida Pellett, Daria Krenitsky, Juilee Thakar and Jennifer Anolik, University of Rochester Medical Center, Rochester, NY

    Background/Purpose: The gut is a key mucosal tissue that can impact the immune system and contribute to systemic inflammation in the setting of increased intestinal…
  • Abstract Number: 0905 • ACR Convergence 2024

    High-Throughput Proteomic Profiling of Sera as a Non-Invasive Method for Identifying Lupus Nephritis Subtypes

    Rufei Lu1, Andrea Fava2, Benjamin Jones3, Peter Izmirly4, Jennifer Anolik5, Chaim Putterman6, David Wofsy7, Matthias Kretzler8, Celine Berthier9, E. Steve Woodle10, Michael Weisman11, Mariko Ishimori12, The Accelerating medicines Partnership: RA/SLE Network13, Betty Diamond14, Jill Buyon15, Michelle Petri16, Richard Furie17, Judith James13 and Joel Guthridge13, 1University of California San Francisco, San Bruno, CA, 2Divison of Rheumatology, Johns Hopkins University, Baltimore, MD, 3Oklahoma State University, Oklahoma City, OK, 4New York University Grossman School of Medicine, New York, NY, 5University of Rochester Medical Center, Rochester, NY, 6Albert Einstein College of Medicine, Safed, Israel, 7University of California San Francisco, SF, CA, 8University of Michigan, Ann Arbor, MI, USA, Ann Arbor, MI, 9University of Michigan, Ann Arbor, MI, 10University of Cincinnati College of Medicine, Cincinnati, OH, USA, Cinncinnati, OH, 11Stanford University, Los Angeles, CA, 12Cedars-Sinai Health System, Los Angeles, CA, 13Oklahoma Medical Research Foundation, Oklahoma City, OK, 14The Feinstein Institutes for Medical Research, Manhasset, NY, 15NYU Grossman School of Medicine, New York, NY, 16Johns Hopkins University School of Medicine, Timonium, MD, 17Northwell Health, Manhasset, NY

    Background/Purpose: Lupus nephritis (LN) treatment decisions are typically informed using histopathological classification based on the International Society of Nephrology/Renal Pathology Society (ISN/RPS) and NIH activity…
  • Abstract Number: 1804 • ACR Convergence 2024

    Investigating Adaptive Immune Receptor Repertoires by Deep Immune Cell Phenotyping in Preclinical Autoimmunity Development

    Aleksandra Bylinska1, Miles Smith1, Rufei Lu1, Benjamin Jones2, Carla Guthridge1, Matthew Caleb Marlin1, Christian Wright3, Susan Macwana3, Wade DeJager3, Marci Beel3, Christopher Lessard1, Cristina Arriens1, Joan Merrill4, Judith James1 and Joel Guthridge1, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2Oklahoma State University, Oklahoma City, OK, 3Oklahoma Medical Research Foundation, Oklahoma City, 4Oklahoma Medical Research Foundation, Oklahoma City 73104, OK

    Background/Purpose: A loss of systemic self-tolerance to anti-nuclear autoantibodies (ANAs) is one of the main hallmarks of SLE. However, most healthy females with ANAs will…
  • Abstract Number: 0015 • ACR Convergence 2024

    Profiling of B and T Cells in Kidney Biopsies from ANCA-associated Vasculitis Patients with Glomerulonephritis at Single-Cell Resolution

    Ana Merino Vico1, Yosta Vegting1, Aldo Jongejan1, Jan Piet van Hamburg1, Perry moerland1, Sander Tas2 and Marc Hilhorst1, 1Amsterdam UMC, Amsterdam, Netherlands, 2Amsterdam UMC, locatie AMC, Amsterdam, Netherlands

    Background/Purpose: Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a small-vessel autoimmune vasculitis, associated with severe lung and kidney impairment. B cells are crucial in AAV…
  • Abstract Number: 0911 • ACR Convergence 2024

    Activating B Cells Facilitates the Discovery of Latent Disease-associated Variants

    David Murphy, Yao Fu, Jennifer Kelly, Richard Pelikan, Graham Wiley and Patrick Gaffney, Oklahoma Medical Research Foundation, Oklahoma City, OK

    Background/Purpose: Although millions of disease-associated variants have been discovered using GWAS, most of these occur in non-coding regions and their mechanistic link to disease is…
  • Abstract Number: 1807 • ACR Convergence 2024

    Identification of HDAC Inhibitor Targeting Type I Interferon and B-cell Abnormalities in Systemic Lupus Erythematosus

    Takehiro Hirayama1, Hyota Takamatsu2 and Atsushi Kumanogoh3, 1Osaka university, ibaraki city, Japan, 2National Hospital Organization Osaka Minami Medical Center, kawachinagano, Japan, 3Osaka University, Osaka, Japan

    Background/Purpose: This study aimed to identify drugs that can inhibit both type I interferon (IFN-I) production and abnormal B-cell maturation and to elucidate the therapeutic…
  • Abstract Number: 0016 • ACR Convergence 2024

    Establishment of a Human 3D In-Vitro Lymphoid Model to Evaluate Germinal Center Biology

    Lichchavi Rajasinghe1, Govinda Rocky Thomas,2, Jee Ho Lee1, Gary Sims1 and Tatiana Ort1, 1Immunology Biosciences, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, 2AstraZeneca Pharmaceuticals, Gaithersburg, MD

    Background/Purpose: Germinal centers (GC) are specialized lymphoid structures found within the B cell follicles of secondary lymphoid tissue formed following infection or immunization. They are…
  • Abstract Number: 1139 • ACR Convergence 2024

    Comprehensive Single-cell Profiling of Diverse Circulating Immune Cells in Idiopathic Inflammatory Myopathies Identifies a Novel Pathogenic Subset of Monocytes

    Shinji Izuka1, Toshihiko Komai2, Hayato Yuuki2, Ikuko Ueda3, Manabu Fujimoto4, Hiroyuki Fukui5, Masaru Takeshita6, Natsuka Umezawa7, Shinsuke Yasuda7, Mitsutaka Yasuda8, Yuichiro Fujieda9, Tatsuya Atsumi9, Takeshi Iwasaki10, Akio Morinobu10, Yuya Kondo11, Isao Matsumoto11, Toshio Kawamoto12, Masakazu Matsushita12, Naoto Tamura13, Taro Iwamoto14, Hiroshi Nakajima14, Ken Yoshida15, Takeo Isozaki16, Nobuyuki Yajima16, Keiichi Sakurai17, Kimito Kawahata17, Yasuyuki Kamata18, Kojiro Sato18, Yoshiya Tanaka19, Akari Suzuki20, Kazuhiko Yamamoto21, Tomohisa Okamura22 and Keishi Fujio2, 1Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan., Tokyo, Japan, 2Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan., Bunkyo, Tokyo, Japan, 3Department of Dermatology, Osaka University Graduate School of Medicine, Suita, Japan., Suita, Japan, 4Department of Dermatology, Osaka University Graduate School of Medicine, Suita, Japan., Suita, Osaka, Japan, 5Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan., Tokyo, Japan, 6Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan, 7Department of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan., Tokyo, Japan, 8Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan., Sapporo, Japan, 9Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, Sapporo, Japan, 10Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan., Kyoto, Japan, 11Department of Rheumatology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan., Tsukuba, Japan, 12Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan., Tokyo, Japan, 13Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, 14Department of Allergy and Clinical Immunology, Chiba University Hospital, Chiba, Japan., Chiba, Japan, 15Division of Rheumatology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan., Tokyo, Japan, 16Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan., Tokyo, Japan, 17Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan., Kawasaki, Japan, 18Division of Rheumatology and Clinical Immunology, Department of Medicine, Jichi Medical University, Tochigi, Japan., Tochigi, Japan, 19Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan, 20Laboratory for Autoimmune Diseases, RIKEN Center for Integrative Medical Sciences, Yokohama, Kanagawa, Japan., Kanagawa, Japan, 21Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan., Laboratory for Autoimmune Diseases, RIKEN Center for Integrative Medical Sciences, Yokohama, Kanagawa, Japan., Kawasaki, Japan, 22Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan., Department of Functional Genomics and Immunological Diseases, Graduate School of Medicine, The University of Tokyo, Japan., Bunkyo, Tokyo, Japan

    Background/Purpose: Idiopathic inflammatory myopathies (IIMs) are heterogeneous diseases, making it crucial to identify distinct pathological processes to improve a treatment strategy. Transcriptomic analyses have revealed…
  • Abstract Number: 1842 • ACR Convergence 2024

    Development of Next Generation CAR T Cell Therapy for the Off-the-shelf Treatment of Autoimmune Diseases Without Conditioning Chemotherapy

    John Goulding1, John Reiser2, Alison O'Connor1, Bryan Hancock1, Jonatan Tuncel1, Brian Groff1, Rina Mbofung1, Daniel Morales-Mantilla1, Allan Williams1, Dan Lu1, Bi-Huei Yang1, Eigen Peralta1, Alma Gutierrez1, Miguel Meza1, Betsy Rezner1, Amanda Sims1, Alec Witty1, Yijia Pan1, Mark Jelcic1, Shohreh Sikaroodi1, Matthew Denholtz1, Tom Lee1, Anil Bagri1, Lilly Wong1, Jode Goodridge1 and Bahram Valamehr1, 1Fate Therapeutics Inc., San Diego, CA, 2Fate Therapeutics Inc, San Diego, CA

    Background/Purpose: Developed initially as a novel strategy to treat B cell malignancies, chimeric antigen receptor (CAR) T cells have now been used to treat multiple…
  • Abstract Number: 0017 • ACR Convergence 2024

    Syndecan-1 Plays a Role in the Pathogenesis of Sjögren’s Syndrome by Inducing B-cell Chemotaxis Through CXCL13-heparan Sulfate Interaction

    Sang Jin Lee1, Nan Young Lee2, Eun Joo Lee3, Ji Ae Jang3, Gun Woo Kim3 and Eon Jeong Nam2, 1Kyungpook National University Hospital, Daegu, Republic of Korea, 2Kyungpook National University Chilgok Hospital, Daegu, Republic of Korea, 3Daegu Fatima Hospital, Daegu, Republic of Korea

    Background/Purpose: Primary Sjögren’s syndrome (pSS) is a prototypical autoimmune disorder with lymphocytic infiltration of exocrine and non-exocrine epithelia, where complex interactions between innate and adaptive…
  • Abstract Number: 1381 • ACR Convergence 2024

    Elimination of CD45RChigh T and B Cells by anti-CD45RC mAb Lead to Efficient Control of Experimental Rheumatoid Arthritis

    Cécile Bergua1, Marine Besnard1, Ghenima Ahmil2, Laure-Helene Ouisse2, Nadège Vimond1, Apolline Salama2, Bérangère Evrard2, Elise Brisebard3, Alexis Collette1, Fréderic Blanchard4, Thibault Larcher3, Ronald Van Brempt1, Benoit Le Goff5, Ignacio Anegon2 and Carole Guillonneau1, 1AbolerIS Pharma, Nantes, France, Nantes, France, 2Nantes Université, INSERM, Center for Research in Transplantation and Translational Immunology, UMR 1064, CNRS, Nantes, France, Nantes, France, 3APEX-UMR703 PAnTher INRA/ONIRIS, France, Nantes, France, 4INSERM UMR1229, Nantes, France, Nantes, France, 5CHU Nantes, France, Nantes, France

    Background/Purpose: CD45RC is an isoform of CD45, a transmembrane tyrosine phosphatase, essential regulator of T and B cells antigen receptor signaling, expressed by most blood…
  • Abstract Number: 2290 • ACR Convergence 2024

    Umbilical Cord-derived Mesenchymal Stem Cells Suppress Sjogren’s Syndrome Pathology

    Yukitomo Hagiwara1, Goh Murayama2, Taiga Kuga2, Yujin Nishioka2, Takumi Saito2, Yu Yamaji2, Tomoko Miyashita2, Makio Kusaoi3, Ken Yamaji2 and Naoto Tamura2, 1Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan, 2Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, 3Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Bunkyo, Tokyo, Japan

    Background/Purpose: Primary Sjögren's syndrome (pSS) is characterized by lymphocytic infiltration of the salivary and lacrimal glands, leading to functional loss and gradually causing dry mouth…
  • Abstract Number: 0036 • ACR Convergence 2024

    Deep Topic Modeling Deconvolves Cell States in Spatial Transcriptomic Profiles of Rheumatoid Arthritis Synovial Tissue

    Preethi Periyakoil1, Melanie Smith2, Meghana Kshirsagar3, Daniel Ramirez4, Edward Dicarlo5, Susan Goodman6, Laura Donlin2 and Christina Leslie7, 1Weill Cornell Medical College, New York, NY, 2Hospital for Special Surgery, New York, NY, 3Microsoft AI for Good, Seattle, 4Hospital for Special Surgery, Cartago, Costa Rica, 5Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, 6Hospital for Special Surgery, New York 10025, NY, 7Memorial Sloan Kettering Cancer Center, New York, NY

    Background/Purpose: Recent single-cell RNA sequencing (scRNA-seq) studies of the rheumatoid arthritis (RA) synovium have highlighted the heterogeneity of cell states present during active disease. It…
  • Abstract Number: 1423 • ACR Convergence 2024

    An Observational Analytical Study on HCV Patients with Sicca Manifestations Before and After Direct-Acting Antivirals in Comparison with Sjogren’s Disease; Infection versus Autoimmunity

    Mohamed Tharwat Hegazy1, Amina Maher2, Tareq Algarf2, Manar Abdul-Aziz2, Osama Ashraf Wafa Mohamed3, Luca Quartuccio4, Naguib Zoheir2, Salvatore De Vita5 and Gaafar Ragab6, 1Faculty of Medicine, Cairo University, Cairo, Egypt, 2Cairo University, Cairo, Egypt, 3Newgiza University, Cairo, Egypt, 4Division of Rheumatology, Department of Medicine (DMED), University of Udine, Udine, Italy, Udine, Italy, 5Udine University, Udine, Italy, 6Cairo University, Egypt, Cairo, Egypt

    Background/Purpose: Hepatitis C virus (HCV) is often associated with autoimmune features and extra-hepatic manifestations. Sicca symptoms are reported in about 30% of the cases. Both…
  • 1
  • 2
  • 3
  • …
  • 12
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology